Publications by authors named "Brinkley A Morse"
Despite their potential, the adoption of nanotechnology in therapeutics remains limited, with only around eighty nanomedicines approved in the past 30 years. This disparity is partly due to the "one-size-fits-all" approach in medical design, which often overlooks patient-specific variables such as biological sex, genetic ancestry, disease state, environment, and age that influence nanoparticle behavior. Nanoparticles (NPs) must be transported through systemic, microenvironmental, and cellular barriers that vary across heterogeneous patient populations.
View Article and Find Full Text PDFArticle Synopsis
- Intravenous immunoglobulin (IVIG) is an immunomodulatory therapy that has potential applications for various neuroimmune conditions, including Guillain-Barré Syndrome and multiple sclerosis, as well as for treating acute COVID-19 and its aftereffects (PASC).
- IVIG works by providing antibodies that help regulate immune responses, which can lead to improved outcomes in severe COVID-19 cases and alleviate persistent symptoms in PASC and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
- Despite its benefits, IVIG use raises concerns due to potential side effects (like anaphylaxis and thrombosis), high costs, and the need for further research to optimize treatment protocols, especially for COVID-